top of page
Search

The 2026 neurodegeneration reset: what actually holds up in human studies


Early 2026 is a good moment to reset the way we talk about neurodegeneration. Not with slogans, and not with false certainty, but with a practical question that respects real lives: what has actually held up in human studies, and what is worth watching next? In clinic, we treat research like a set of road signs. Some are solid and well-lit. Some are temporary. Some are misleading. The job is not to pretend we have a map for every side street. The job is to keep you off the cliffs and moving toward the routes that are most defensible.

This blog focuses on food, lifestyle, and supplements, because these are the levers most people can pull today. It also keeps one rule throughout: the closer a study gets to outcomes that matter to daily living, the more weight we give it. Biomarkers can be interesting. Function and quality of life are the point.



The bacon-to-beans swap that shows how nutrition science becomes usable


If you have ever felt stuck between “never eat this” and “nothing matters anyway,” this is your bridge. In January 2025, a long-term cohort analysis reported that higher red meat intake, particularly processed red meat (emphasis on the word 'processed'), was associated with higher dementia risk and worse cognition. Crucially, the paper did something more helpful than a ban. It asked a substitution question: if you replace one daily serving of processed red meat with alternatives such as nuts and legumes, fish, or poultry, what changes? Those modeled replacements were associated with lower dementia risk (Li et al., 2025). This is the kind of paper we like, not because it is perfect, but because it is usable. It does not reduce life to “never eat X.” It asks the real-world question: “If I swap this for that, what changes?” It also helps people avoid a common trap. Many patients try to “eat healthier” by removing foods and then accidentally lowering protein or calories, which is rarely a win in neurodegeneration.


The critical nuance is that this is observational. It cannot prove causation and the cohorts are not perfectly representative of all populations. But if your goal is a practical, evidence-informed change that also supports vascular and metabolic health, swapping processed meats for legumes, nuts, fish, and poultry is a reasonable place to start (Li et al., 2025).



Ultra-processed foods: the Trojan horse in the aisle


We hear two reactions to ultra-processed foods (UPFs). One is panic. The other is dismissal. The science asks for a third posture: curiosity with standards.


In 2025, a Framingham Heart Study analysis reported an interaction with age: among participants younger than the median age at baseline, each additional serving per day of UPFs was associated with higher Alzheimer’s disease risk, whereas the association was not the same in the older subgroup (Weinstein et al., 2025).


Around the same time, a Neurology study found that long-term UPF intake was associated with higher odds of multiple prodromal Parkinson’s features, including constipation and probable REM sleep behaviour disorder symptoms, depressive symptoms, and body pain (Wang et al., 2025).


Here is the realism that patients deserve. These are observational studies. They cannot prove UPFs cause Alzheimer’s or Parkinson’s. But they point to a pressure pattern that matches what we already know about cardiometabolic strain. UPFs often raise glycaemic load, disrupt appetite regulation, displace fibre and micronutrients, and push insulin resistance in susceptible people. If blood pressure is the water mains of brain health, UPFs are often the daily habits that make turning the tap harder than it needs to be.


One important scientific housekeeping point: a prior Framingham Offspring Study report linking UPFs to dementia was later retracted. That does not mean “UPFs are safe,” and it does not mean “UPFs are guilty.” It means the evidence base is self-correcting, and we should privilege findings that are independently reproduced and methodologically sound (Wang et al., 2023, retracted).


If you only take one food-level action into 2026, frame it as a substitution, not a ban: reduce UPFs by replacing the easiest “default” items first. The brain does not need perfection. It needs the trend line to bend in the right direction.



Parkinson’s, the gut, and the first signs of a more serious supplement conversation


The microbiome space has been noisy for years. In 2025, it got a bit more adult.

A randomised clinical trial in Movement Disorders evaluated a four-strain probiotic in Parkinson’s disease and examined gut microbiota composition, inflammatory markers, and symptoms (Leta et al., 2025). This does not mean “probiotics treat Parkinson’s.” It means that targeted gut interventions are increasingly being tested with endpoints that patients care about and clinicians can track. In practice, the most defensible near-term use case remains symptom-centred, especially constipation, which can affect quality of life, medication timing, and sleep.


The nuance is that probiotic studies vary by strain, dose, duration, and patient phenotype. A trial is not proof that every supermarket probiotic will help. But it is proof that the question can be asked rigorously, and that is progress (Leta et al., 2025).


The clinically useful translation is this: if you have Parkinson’s plus constipation, bloating, unpredictable “time to on,” or mood shifts that track with your gut, it may be rational to trial a targeted, evidence-aligned probiotic approach under supervision, and to treat it as an experiment with defined outcomes (stool form, frequency, medication response pattern, non-motor symptom scores), not as faith. (Leta et al., 2025)



ALS/MND: where hope needs guardrails, not hype


ALS is where we are most careful with language. Not because we are pessimistic, but because patients and families pay the price of overconfident claims. Across 2025, two nutrition-adjacent themes held up better than most in human evidence: movement done wisely, and the idea that timing and energy balance matter.


A 2025 systematic review and meta-analysis of randomised trials suggested that exercise interventions can improve certain functional measures in ALS, while not consistently improving fatigue or key respiratory measures across studies (Ren et al., 2025). That fits what many people with ALS already know in their bodies: movement can support function and wellbeing when it respects fatigue and recovery, but “more” is not automatically “better.”


Respiratory support is part of that same story. A 2025 systematic review and meta-analysis of respiratory muscle training trials reported improvements in ventilatory function, particularly respiratory muscle strength, while also noting that the overall evidence base remains limited (Benzo-Iglesias et al., 2025).


On the supplement side, ultra-high-dose methylcobalamin (a pharmacologic B12 strategy, typically delivered by injection) remains one of the more credible signals in ALS, because it has randomised trial evidence in early-stage disease (Oki et al., 2022). Then in late 2025, an open-label extension reported longer-term safety and tolerability findings for 50 mg intramuscular methylcobalamin in ALS (Kaji et al., 2025). A further real-world signal of “this is not fringe” is that Japan has approved high-dose mecobalamin for ALS-related functional decline, which is a regulatory step built on clinical trial data, not influencer enthusiasm.


A practical way to interpret this without overpromising is to treat the evidence like a two-part safety and efficacy file. The randomised trial supports a disease-modifying signal in a defined early-stage subgroup (Oki et al., 2022). The extension is more like a long safety road test. Useful, but not definitive for efficacy (Kaji et al., 2025). For patients and clinicians, feasibility and safety are not footnotes. They are part of what makes an intervention real.



Dementia and the “fat story”: omega-3, lipids, and why sex differences may matter


Patients often ask, “Should I take omega-3?” The honest answer is: omega-3 is not one question. It is several questions wearing one coat.


A 2025 Alzheimer’s & Dementia paper reported that lipid changes associated with Alzheimer’s disease were prominent in women, including fewer highly unsaturated lipids and more saturated lipids. That does not prove that omega-3 supplements prevent Alzheimer’s. But it does strengthen a more sophisticated idea: some people may have a measurable lipid vulnerability that could make nutrition interventions more relevant for them than for others. Precision nutrition is not a buzzword when it is anchored to measurable biology. (Wretlind et al., 2025)


On the supplementation evidence, a 2025 dose–response meta-analysis of RCTs found mixed certainty across cognitive domains and suggested that effects, where present, may depend on dose and context, with overall evidence quality varying by outcome. The practical implication is not “everyone take high-dose fish oil.” It is: if you are going to use omega-3, define the goal (triglycerides, inflammation, cognitive domain support), define the dose, and measure something that can change. (Shahinfar et al., 2025)


Separately, an umbrella review in 2023 reported that dietary omega-3 intake was associated with lower risk of all-cause dementia or cognitive decline, which again does not prove causality but supports prioritising food sources as a base layer. Food is not magic, but it is a daily exposure you actually control. (Wei et al., 2023)



The GLP-1 question: what semaglutide is, and why neurologists care


Semaglutide is a GLP-1 receptor agonist, a medication class used for type 2 diabetes and obesity. The reason it entered neurology conversations is that GLP-1 signaling may influence inflammation, insulin sensitivity, vascular function, and possibly neuroinflammatory pathways. In plain terms: it is not a “brain drug,” but it touches systems that the brain depends on.


The big Alzheimer’s trials (EVOKE / EVOKE+) reported topline results in late 2025 that did not meet primary clinical endpoints. That is disappointing, and it is also scientifically useful: it suggests that improving metabolic and inflammatory biomarkers, at least at the magnitude achieved, may not be enough to slow cognitive decline in established early Alzheimer’s over that timeframe. Full peer-reviewed analyses will matter because topline results are not the same as granular subgroup and biomarker storylines. (Alzheimer Europe, 2025; UK DRI, 2025; Alzheimer’s Drug Discovery Foundation, 2025)


For Parkinson’s, the story is still open. A 2025 published protocol (MOST-ABLE) describes a phase 2 randomised, placebo-controlled trial of oral semaglutide in Parkinson’s with detailed clinical and imaging endpoints. That is exactly the kind of “watch this space” trial design that could produce interpretable results. (Kimura et al., 2025)


(Alzheimer Europe, 2025; UK DRI, 2025; Alzheimer’s Drug Discovery Foundation, 2025; Kimura et al., 2025)



The most brain-active lifestyle lever is the one people skip because it is boring


If neurodegeneration were a city under pressure, blood pressure would be the water mains. When the mains run too hard for too long, small cracks accumulate everywhere. You do not notice the damage until one day the streets start sinking.


In 2025, a large randomised trial in rural China tested a stepped-care blood pressure programme delivered by trained community providers in adults with uncontrolled hypertension. The intervention reduced blood pressure and lowered the risk of all-cause dementia compared with usual care (He et al., 2025).


This is not a “food study,” yet it may be one of the most practically important brain-health papers of the year. It tells us that protecting the brain is not only about plaques, tangles, or proteins. It is also about keeping perfusion and vascular integrity stable enough to preserve reserve (He et al., 2025).



Lifestyle works best when it stops behaving like a motivational poster


Many people tell us, “I know what to do. I just cannot make it stick.” That is not a character flaw. It is biology plus modern life.


The US POINTER randomised clinical trial (published 2025) tested two 2-year multi-domain lifestyle programmes in older adults at increased risk of cognitive decline. Both programmes included familiar ingredients: physical activity, dietary change aligned with Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) principles, cognitive and social challenge, and health monitoring. Both groups improved global cognition, with greater improvement in the more structured, supported programme (Baker et al., 2025).


This matters because it moves lifestyle from ideology to engineering. The brain does not respond well to occasional heroic effort. It responds to repeatable systems. POINTER does not promise miracles, but it does support a grounded kind of hope: structure changes the odds (Baker et al., 2025).



What to watch in 2026: the trial calendar that could change clinic conversations


If 2025 was about signals and stronger methods, 2026 is about results that can actually close arguments. Below are the studies most likely to shift what we can responsibly say in clinic from “interesting idea” to “evidence-informed option.”


ALS/MND: where “more energy” stops being a slogan and becomes a testable prescription


  • OptiCALS: a pragmatic, clinic-relevant question, whether structured dietetic care and nutritional management can shift outcomes people actually live with in ALS. Follow-up is scheduled to finish September 2026, with results expected after that (Peace et al., 2025).


  • LIPCAL-ALS II: higher-dose, high-calorie supplementation at scale, designed to test whether energy support is survival-relevant, or only theoretically appealing. Recruitment began in 2024 and the intervention window is long enough that 2026–2027 is the realistic results horizon (MND-NET, 2026).


  • KETO-ALS (NCT04820478): ketone ester strategies in ALS, which matters because it forces the “brain energy” argument to leave social media and enter measurement. Trial registry listings report an estimated primary completion in October 2025, making 2026 a plausible publication window (ClinicalTrials.gov, 2026b; NEALS, n.d.).



Parkinson’s: gut, glucose, and the end of “one-size probiotics”


  • MOST-ABLE: oral semaglutide as a disease-modifying test in Parkinson’s, built with a washout design intended to help distinguish symptomatic effects from potential slowing of progression (Kimura et al., 2025).


  • MED-PARK (NCT06705517): a 6-month Mediterranean-diet programme in Parkinson’s with immune and microbiome readouts. This is important because it is diet as an intervention with measurable biology, not just advice (Pirovano et al., 2025; ClinicalTrials.gov, 2026e).


  • Microbiota intervention in prodromal Parkinson’s (NCT03575195): a multi-year microbiome-focused study with an estimated primary completion of August 2026, aimed at early (prodromal) features rather than late-stage symptoms (ClinicalTrials.gov, 2026a).


  • EJS ACT-PD platform trial: not a diet trial, but highly relevant to clinics because it speeds up answers by testing multiple candidates efficiently.  Uursodeoxycholic acid (UDCA) is planned to be added in 2026, a compound many patients ask about because it sits on the border between prescription and “supplement-like” narratives (Cure Parkinson’s, 2025; MRC Clinical Trials Unit at UCL, 2025).



Dementia and Alzheimer’s risk: where “fasting” becomes a protocol, not a personality


  • NIBBLE (NCT06682767): a fasting-mimicking diet intervention in middle-aged APOE ε4 carriers, looking at cognition, blood biomarkers, and MRI-related outcomes. Trial listings report an estimated primary completion in November 2026 (ClinicalTrials.gov, 2026d).


  • MIND diet education in mild cognitive impairment (NCT05975723): an example of “implementable nutrition,” where the intervention is designed to be teachable and scalable. Trial listings indicate an estimated primary completion in August 2025, making 2026 a plausible window for full analysis and publication (ClinicalTrials.gov, 2026c; CenterWatch, 2023).


  • MIND diet in a large middle-aged and older cohort (NCT06417749): a pragmatic, big-sample trial (n≈1200). Listings report an estimated completion date of October 10, 2025, which means publication could materially influence what clinicians can recommend without overpromising (CenterWatch, 2024).


A note on reading trial calendars: registration is not evidence. But watching the right human trials helps patients and clinicians



How You Nutrition Clinic fits into this, without selling false certainty



At You Nutrition Clinic, the value is not in selling certainty. It is in building a plan that respects two truths at once:


  1. These diseases are serious, complex, and not cured by “clean eating.”

  2. Human evidence increasingly supports targeted levers that can improve resilience, symptoms, and sometimes risk trajectories.



That means we focus on interventions with the best signal-to-hype ratio: adequate energy and protein where clinically relevant (especially in ALS/MND), constipation and microbiome-support strategies where appropriate, blood pressure and cardiometabolic optimisation as brain infrastructure, and realistic lifestyle programming that behaves like a dose, not a slogan.



🧩  Connect with Us



For research updates, simple tools you can use at home and ongoing support for brain and nervous-system health, follow us on Instagram:


👉 @nutritionandthebrain


Stay informed.

Stay supported.

Support your brain. 🧠💛



References


Alzheimer’s Association. (2025, November 24). Alzheimer’s Association statement following release of topline data from EVOKE and EVOKE+ phase 3 trials of oral semaglutide in early symptomatic Alzheimer’s disease. Retrieved January 6, 2026, from https://www.alz.org/news/2025/alzheimers-association-statement-following-release-of-topline-data-from-evoke-and-evoke-plus-phase-3-trials


Baker, L. D., Espeland, M. A., Whitmer, R. A., et al. (2025). Two-year multidomain interventions and cognition in older adults at increased risk of Alzheimer disease: The U.S. POINTER randomized clinical trial. JAMA, 334(10), 938–951. https://doi.org/10.1001/jama.2025.12923


Benzo-Iglesias, M. J., Rocamora-Pérez, P., et al. (2025). Effect of respiratory muscle training on respiratory function in people with amyotrophic lateral sclerosis: A systematic review and meta-analysis. Chronic Respiratory Disease, 19, 17534666251346095. https://doi.org/10.1177/17534666251346095


CenterWatch. (2023, August 2). MIND diet and cognitive function in adults with MCI (NCT05975723). Retrieved January 6, 2026, from https://www.centerwatch.com/clinical-trials/listings/NCT05975723/mind-diet-and-cognitive-function-in-adults-with-mci


CenterWatch. (2024, May 12). MIND diet and cognitive function in middle-aged and older adults (NCT06417749). Retrieved January 6, 2026, from https://www.centerwatch.com/clinical-trials/listings/NCT06417749/mind-diet-and-cognitive-function-in-middle-aged-and-older-adults


ClinicalTrials.gov. (2026a). Microbiota intervention for prodromal Parkinson’s disease (NCT03575195). Retrieved January 6, 2026, from https://clinicaltrials.gov/study/NCT03575195


ClinicalTrials.gov. (2026b). Efficacy and tolerability of beta hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (ALS) (NCT04820478). Retrieved January 6, 2026, from https://clinicaltrials.gov/study/NCT04820478


ClinicalTrials.gov. (2026c). MIND diet and cognitive function in adults with mild cognitive impairment (MCI) (NCT05975723). Retrieved January 6, 2026, from https://clinicaltrials.gov/study/NCT05975723


ClinicalTrials.gov. (2026d). A nutritional intervention for body, brain, and longevity effects (NIBBLE) (NCT06682767). Retrieved January 6, 2026, from https://clinicaltrials.gov/study/NCT06682767


ClinicalTrials.gov. (2026e). Mediterranean diet effects on Parkinson’s disease (MED-PARK) (NCT06705517). Retrieved January 6, 2026, from https://clinicaltrials.gov/study/NCT06705517

Cummings, J. L. (2025). EVOKE and EVOKE+: Two phase 3 randomised placebo-controlled trials of oral semaglutide in early Alzheimer’s disease [Conference slides]. Clinical Trials on



Cure Parkinson’s. (2025, October 16). EJS ACT-PD recruitment announcement. Retrieved January 6, 2026, from https://cureparkinsons.org.uk/2025/10/ejs-act-pd-recruitment-announcement/


He, J., Zhao, C., Zhong, S., et al. (2025). Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: An open-label, blinded-endpoint, cluster-randomized trial. Nature Medicine, 31(6), 2054–2061. https://doi.org/10.1038/s41591-025-03616-8


Kaji, R., Nishi, Y., et al. (2025). Clinical safety of ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: An open-label extension study. Journal of the Neurological Sciences, 480, 125701. https://doi.org/10.1016/j.jns.2025.125701


Kimura, K., et al. (2025). MOST-ABLE: A trial evaluating oral semaglutide as a potential disease-modifying therapy for Parkinson’s disease (protocol). BMJ Open, 15, e112318. https://doi.org/10.1136/bmjopen-2025-112318


Leta, V., Zinzalias, P., Batzu, L., et al. (2025). Effects of a multi-strain probiotic on gut microbiota, inflammation, and symptoms in Parkinson’s disease: A randomized clinical trial.


Movement Disorders, 40(12), 2710–2721. https://doi.org/10.1002/mds.70047

Li, Y., Li, Y., Gu, X., et al. (2025). Long-term intake of red meat and risk of dementia and cognitive decline. Neurology, 104(3), e210286. https://doi.org/10.1212/WNL.0000000000210286


MND-NET. (2026). LIPCAL-ALS II study: High-calorie, fat-based supplementation in ALS. Retrieved January 6, 2026, from https://mnd-net.de/en/research-and-science/lipcal-als-2-study/


MRC Clinical Trials Unit at UCL. (2025, October 16). Largest-ever Parkinson’s disease trial opens across UK. Retrieved January 6, 2026, from https://www.mrcctu.ucl.ac.uk/news/news-stories/2025/october/largest-ever-parkinson-s-disease-trial-opens-across-uk/


Northeast ALS Consortium. (n.d.). Efficacy and tolerability of beta hydroxybutyrate ester in patients with amyotrophic lateral sclerosis (ALS) (NCT04820478). Retrieved January 6, 2026, from https://neals.org/als-trials/nct04820478


Oki, R., Izumi, Y., et al. (2022). Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: A randomized clinical trial. JAMA Neurology, 79(6), 575–583. https://doi.org/10.1001/jamaneurol.2022.0901


Peace, A., White, D. A., Hackney, G., Bradburn, M., et al. (2025). Optimising nutrition in amyotrophic lateral sclerosis (OptiCALS): Study protocol for a cluster randomised controlled trial. BMJ Open, 15(5), e096098. https://doi.org/10.1136/bmjopen-2024-096098


Pirovano, E., Marino, F., Rossi, E., et al. (2025). Modified Mediterranean diet effects on Parkinson’s disease (MED-PARK): A single-centre randomised controlled trial protocol. BMJ Open, 15(10), e101946. https://doi.org/10.1136/bmjopen-2025-101946


Ren, S., Che, X., Hu, S., Feng, X., Zhang, J., & Shi, P. (2025). Effects of exercise on physical function in patients with amyotrophic lateral sclerosis: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Neurology, 16, 1499407. https://doi.org/10.3389/fneur.2025.1499407


Wang, K., Tang, W., Hao, X., & Zhao, J. (2023). Retracted: Ultra-processed foods and risk of dementia: Framingham Offspring Study. Alzheimer’s & Dementia, 19(12), 5988. https://doi.org/10.1002/alz.13351


\Wang, P., et al. (2025). Long-term consumption of ultraprocessed foods and odds of prodromal features of Parkinson disease. Neurology, 104(11), e213562. https://doi.org/10.1212/WNL.0000000000213562


Weinstein, G., Koijs, D., Banerjee, A., Beiser, A., et al. (2025). Association of ultra-processed foods with Alzheimer’s disease in the Framingham Heart Study. The Journal of Prevention of Alzheimer’s Disease, 12(2), 440–449. https://doi.org/10.1016/j.tjpad.2024.100042

 
 
 

Comments

bottom of page